Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 1997 Nov;15(11):3394-8.

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

Author information

  • 1University of Chicago, and Northwestern University Medical School, Chicago, IL 60637, USA. wmstadle@mcis.bsd.uchicago.edu

Abstract

PURPOSE:

To determine the activity of single-agent gemcitabine in previously untreated patients with metastatic transitional cell cancer.

METHODS:

Forty patients with measurable disease and a Karnofsky performance status > or = 60% were enrolled at five institutions between March 1994 and October 1995. Treatment consisted of gemcitabine (1,200 mg/m2) administered weekly times three on a 4-week cycle. One patient was ineligible for response evaluation because pathology review showed a metastatic melanoma. Responses were confirmed by all investigators and an independent radiologist and were maintained for at least 4 weeks.

RESULTS:

There were four complete and seven partial responses, for an overall response rate of 28%. Responses were seen at all sites, including liver. Median progression-free and overall survival times were 20 and 54 weeks, respectively. Toxicity was mild, with only two grade 4 toxicities. Twenty-five percent of patients experienced grade 3 neutropenia or thrombocytopenia that was rapidly reversible.

CONCLUSION:

Gemcitabine exhibits significant activity in metastatic transitional cell cancer with minimal toxicity, but survival remains short. Trials of gemcitabine in combination with other active agents are thus suggested.

PMID:
9363871
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk